Speaker Name: Dr. Javed Butler, Patrick H. Lehan Chair, Cardiovascular Research, Professor & Chairman, Department of Medicine, University of Mississippi, USA

Access this expert session to:

• Gain insights into the application of AHA PREVENT with ASCVD tools for improved long-term CV and HF risk assessment.
• Recognize key risk enhancers, including family history, metabolic syndrome, obesity, prediabetes, and CAC in guiding therapy.
• Differentiate CV benefits of glucose-lowering therapies with SGLT2i for HF/CV death and GLP-1 RA for MI and stroke.
• Identify practical strategies for HF prevention using BP control and markers such as LVH, hs-troponin, NT-proBNP, and albuminuria.
• Apply integrated CKM syndrome management with RAS blockers, SGLT2i, GLP-1 RA, and non-steroidal MRAs.